A comprehensive retrospective cohort analysis reveals striking efficacy differences in heart failure treatment based on patient genetics. Among 2,847 patients carrying pathogenic variants in cardiomyopathy-associated genes, those receiving dapagliflozin demonstrated a 32% reduction in heart failure risk—substantially outperforming standard medications. In comparison, ACE inhibitors achieved an 18% risk reduction, beta blockers 15%, and standard care alone only 8% in this genetically defined population. These findings underscore the importance of genetic stratification in drug selection and suggest that one-size-fits-all treatment approaches may leave vulnerable patients at unnecessary risk. The research from Mass General Brigham and the Broad Institute indicates that sarcomere gene variants, found in approximately 1 in 500 individuals, represent a critical marker for identifying optimal candidates for dapagliflozin therapy. Read the full article on GMJ Newsroom.
Was this article helpful?
